Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. American Psychedelic Practitioners Association; BrainFutures. Professional Practice Guidelines for Psychedelic-Assisted Therapy. 1st ed. Published 2023. Accessed February 6, 2026. https://www.brainfutures.org/wp-content/uploads/2023/08/Professional-Practice-Guidelines-for-Psychedelic-Assisted-Therapy-Aug-2023.pdf.
2. Bathje GJ, Majeski E, Kudowor M. Psychedelic integration: an analysis of the concept and its practice. Front Psychol. 2022;13:824077.
3. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268-1278.
4. Chaves TV, Wilffert B, Sanchez ZM. Overdoses and deaths related to the use of ketamine and its analogues: a systematic review. Am J Drug Alcohol Abuse. 2023;49(2):141-150.
5. Dore J, Turnipseed B, Dwyer S, et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs. 2019;51(2):189-198.
6. Drozdz SJ, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: a systematic narrative review of the literature. J Pain Res. 2022;15:1691-1706.
7. Fang S, Yang X, Zhang W. Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. Front Psychiatry. 2024;15:1359088.
8. Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. Published 2023. Accessed February 6, 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine.
9. Gukasyan N, Griffiths RR, Yaden DB, Antoine D, Nayak SM. Serotonergic antidepressant use is associated with weaker psilocybin effects. OSF Preprints. Published online 2022.
10. Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973.
11. McAlpine RG, Blackburne G, Kamboj SK. Development and psychometric validation of a novel scale for measuring "psychedelic preparedness." Sci Rep. 2024;14(1):3280.
12. McGuire AL, Cohen IG, Sisti D, et al. Developing an ethics and policy framework for psychedelic clinical care: a consensus statement. JAMA Netw Open. 2024;7(6):e2414650.
13. Modlin NL, Williamson V, Goodwin GM, et al. Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment. EClinicalMedicine. 2025;90:103692.
14. Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54(5):240-245.
15. Neumann J, Dimov K, Azatsian K, Hofmann B, Gergs U. Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans. Life Sci. 2024;398:55-64.
16. Oregon Health Authority. Oregon psilocybin services data dashboard. Accessed January 14, 2026. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Data-Dashboard.aspx.
17. Palmer M, Maynard OM. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J. 2022;19(1):81.
18. Sabé M, Sulstarova A, Glangetas A, et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol Psychiatry. 2025;30(3):1223-1255.
19. Simonsson O, Goldberg SB, Osika W, et al. Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychol Med. 2025;55:e99.
20. Vizgan G, Huamán M, Rychik K, Edeson M, Blaivas JG. Ketamine-induced uropathy: a narrative systemic review of surgical outcomes of reconstructive surgery. BJUI Compass. 2023;4(4):377-384.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.